Clinically, lidocaine has no vasoconstrictive action, and adrenaline is added to prolong its effect. It has been reported that L-DOPA binds to GPR143 receptor and causes vasoconstriction via the α1 receptor. However, effects of L-DOPA on the duration of lidocaine anesthesia remain unclear. 0.25% lidocaine with various ligands is injected intracutaneously into the back of guinea pigs. The number of times without response to stimulus was measured. L-DOPA dose-dependently prolonged the duration of lidocaine anesthesia. Addition of caribidopa, a dopa decarboxylase inhibitor, to 1 μM L-DOPA extended the duration of lidocaine anesthesia. 1 μM DOPA CHE, an inhibitor of GPR143, inhibited the prolongation of lidocaine with 1 μM L-DOPA. 0.25% lidocaine with 1 μM L-DOPA were combined with 1 μM yohimbine, 1 μM prazosin, 1 μM JP1302, 10 μM BRL44408, 10 μM indoramin, 0.25 μM BMY7378, 5 μM cyclazosin, 1 nM silodosin respectively. After mixing, the effect of various antagosits on lidocaine with 1 μM L-DOPA were examined. As a result, antagonists other than 10 μM BRL44408 and 0.25 μM BMY7378 decreased the duration of lidocaine anesthesia with 1 μM L-DOPA. These results indicated that peripheral vasoconstrictor activity of lidocaine with 1 μM L-DOPA is mediated at least by α_2C, α_1A, α_1B receptors.